查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
卵巢癌症治療藥的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各類藥物，各腫瘤類型，各流通管道，各地區(2017年～2027年)
市場調查報告書
商品編碼
1152252

卵巢癌症治療藥的全球市場 - 產業規模，佔有率，趨勢，機會，預測:各類藥物，各腫瘤類型，各流通管道，各地區(2017年～2027年)

Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Drug Class, By Tumor Type, By Distribution Channel, By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球卵巢癌症治療藥的市場規模，在預測期間內的2023年～2027年預計達成驚人的成長。

卵巢癌症治療藥的市場，由於近幾年的卵巢癌症患者數增加而在非常有利的情況下成長，在不久的將來，預計在已開發國家中大幅成長。還有高齡女性人口率的上升，推動在預測期間內的全球卵巢癌症治療藥市場。此外，市場企業和各種研究機關，對卵巢癌治療藥的開發的研究開發活動活性化。

本報告提供全球卵巢癌症治療藥市場相關調查分析，各市場區隔、各地區的市場規模、佔有率預測，市場動態，企業簡介等系統性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19對全球卵巢癌症治療藥市場的影響

第4章 VOC(客戶的迴響)

第5章 臨床試驗分析

第6章 專利分析

第7章 全球卵巢癌症治療藥市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類藥物(烷化劑，有絲分裂抑制劑，抗風濕劑，抗乾癬劑，VEGF/VEGFR抑制劑，PARP抑制劑，抗腫瘤劑，其他)
    • 各腫瘤類型(表皮性卵巢癌症，卵巢低惡性度腫瘤，生殖細胞瘤瘤，性繩索間品質腫瘤)
    • 各流通管道(院內藥局，零售藥局，線上藥局)
    • 各企業(2021年)
    • 各地區
  • 市場地圖

第8章 北美的卵巢癌症治療藥市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類藥物
    • 各腫瘤類型
    • 各流通管道
    • 各國
  • 北美:各國分析
    • 美國
    • 墨西哥
    • 加拿大

第9章 歐洲的卵巢癌症治療藥市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類藥物
    • 各腫瘤類型
    • 各流通管道
    • 各國
  • 歐洲:各國分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第10章 亞太地區的卵巢癌症治療藥市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類藥物
    • 各腫瘤類型
    • 各流通管道
    • 各國
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第11章 南美的卵巢癌症治療藥市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類藥物
    • 各腫瘤類型
    • 各流通管道
    • 各國
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第12章 中東、非洲的卵巢癌症治療藥市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類藥物
    • 各腫瘤類型
    • 各流通管道
    • 各國
  • MEA:各國分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第13章 市場動態

  • 促進因素
  • 課題

第14章 市場趨勢與開發

第15章 競爭情形

  • AstraZeneca, Plc.
  • GlaxoSmithKline, Plc.
  • Merck & Co.
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Amgen Inc.
  • C.H. Boehringer Sohn Ko. KG
  • Novartis AG

第16章 策略性建議

簡介目錄
Product Code: 12865

The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027. Ovarian Cancer is one of the most severe and common cancer that affects the women these days. The ovaries in this malignancy undergo irregular cell proliferation, which can invade or negatively impact other body parts like the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes. The early stages of ovarian cancer are accompanied by a few indistinct symptoms that become more obvious as the malignancy progresses. These signs include bloating, pelvic pain, abdominal swell, and appetite loss. Ovarian Cancer risk is higher in women who have ovulated more frequently throughout their life, which can also include women who have never given birth and those who started ovulating at a young age. According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer. 50% of women who carry BRCA1 or BRCA2 gene mutations will get breast or ovarian cancer. The most frequent type of ovarian cancer, accounting for 95% of occurrences worldwide, is ovarian carcinoma.

Growing Prevalence of Ovarian Cancer

The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases. The American Cancer Society reports that in 2016, there were approximately 22,280 new instances of ovarian cancer diagnosed, resulting in 14,240 fatalities in the United States. Ovarian cancer accounted for 1.3% of the incidence rate and 2.4% of all fatalities attributable to cancer in 2016, according to statistics from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. There will be 23,820 new cases of ovarian cancer recorded in 2020, and the American Cancer Society believes that 1 in 75 women will get ovarian cancer during their lifetimes, with a 1 in 100 risks that she will pass away from it. As of 2017, 1,580 new ovarian cancer cases are anticipated to have been detected, making about 2.5% of all new cancer cases in the nation, according to the Australian Government's Cancer Australia. 1,047 fatalities are anticipated because of this in 2017. Therefore, it is anticipated that the ovarian cancer drugs sector will soon experience significant growth in developed nations.

Increasing Elderly Female Population

The increase in the percentage of the elderly female population is expected to boost the global ovarian cancer drugs market during the forecast period. As the population of old females increases, they are projected to be suffering from more gynecological problems. For instance, according to the World Population Prospects, there were about 9.5% females above the age group of 60 years as of 2021, from which most of the female population are susceptible to gynecological infections or diseases or cancer. Ovarian cancer prevalence is often low in women under the age of 40. Most of the ovarian cancer cases are observed among women 60 years of age and older, according to the American Cancer Society. 7,378 new cases of ovarian cancer were reported in the nation in 2014, with approximately 53% of those cases being identified in women 65 years of age and older, according to Cancer Research UK.

Increasing Research & Development Activities to Develop Ovarian Cancer Drugs

The growing prevalence of ovarian cancer has made the companies operating in the market along with different research organizations to increase their research & development activities in order to develop a potential drug treatment for ovarian cancer. Companies in the pharmaceutical business are increasingly coming up with novel drug combinations to treat ovarian cancer. To treat complex medical diseases, combination medications combine two or more active pharmaceutical ingredients (APIs) into a single dosage form. To lower manufacturing costs, boost compliance and efficiency, enhance medication concordance, increase profitability, and lessen side effects, pharmaceutical companies in the ovarian cancer medications market are investing in the research and development of novel products such as combination drugs. For instance, Roche's well-known tranquilizer Avastin (bevacizumab), which is used to treat advanced stage (III or IV) ovarian cancer, is a combination drug approved by the FDA that contains ingredients like carboplatin and paclitaxel.

Market Segmentation

The global ovarian cancer drugs market is segmented into by drug class, by tumor type, by distribution, by region. Based on by drug class, the market can be fragmented into alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, antineoplastics and others. Based on tumor type, the market can be categorized into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor. Based on distribution channel, the market can be fragmented into hospital pharmacies, retail pharmacies, online pharmacies. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa and South America. The United States held the biggest market in North America region and is expected to be a lucrative market in the forecast period as the government is investing in research for new drugs for the easy detection of ovarian cancer for the affected people.

Market Players

AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG are some of the leading players operating in the global ovarian cancer drugs market.

Report Scope:

In this report, global ovarian cancer drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Drug Class:

  • Alkylating Agents
  • Mitotic Inhibitors
  • Antirheumatics
  • Antipsoriatics
  • VEGF/VEGFR Inhibitors
  • PARP Inhibitors
  • Antineoplastics
  • Others

Ovarian Cancer Drugs Market, By Tumor Type:

  • Epithelial Ovarian Cancer
  • Ovarian Low Malignant Potential Tumor
  • Germ Cell Tumor
  • Sex Cord-Stromal Tumor

Ovarian Cancer Drugs Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Ovarian Cancer Drugs Market

4. Voice of Customer

5. Clinical Trial Analysis

6. Patent Analysis

7. Global Ovarian Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others)
    • 7.2.2. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
    • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.4. By Company (2021)
    • 7.2.5. By Region
  • 7.3. Market Map

8. North America Ovarian Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Tumor Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Ovarian Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Ovarian Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Ovarian Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By Distribution Channel

9. Europe Ovarian Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Tumor Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Ovarian Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Germany Ovarian Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Italy Ovarian Cancer Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Tumor Type
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Spain Ovarian Cancer Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Tumor Type
        • 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Ovarian Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Tumor Type
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Ovarian Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Tumor Type
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. India Ovarian Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Tumor Type
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Japan Ovarian Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Tumor Type
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. South Korea Ovarian Cancer Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Class
        • 10.3.4.2.2. By Tumor Type
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Australia Ovarian Cancer Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Class
        • 10.3.5.2.2. By Tumor Type
        • 10.3.5.2.3. By Distribution Channel

11. South America Ovarian Cancer Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Tumor Type
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Ovarian Cancer Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Tumor Type
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Argentina Ovarian Cancer Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Tumor Type
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. Colombia Ovarian Cancer Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Tumor Type
        • 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Ovarian Cancer Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Class
    • 12.2.2. By Tumor Type
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Ovarian Cancer Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Drug Class
        • 12.3.1.2.2. By Tumor Type
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Saudi Arabia Ovarian Cancer Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Drug Class
        • 12.3.2.2.2. By Tumor Type
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. UAE Ovarian Cancer Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Drug Class
        • 12.3.3.2.2. By Tumor Type
        • 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. AstraZeneca, Plc.
  • 15.2. GlaxoSmithKline, Plc.
  • 15.3. Merck & Co.
  • 15.4. Clovis Oncology, Inc.
  • 15.5. F. Hoffmann-La Roche AG
  • 15.6. Bristol-Myers Squibb Co.
  • 15.7. Eli Lilly and Company
  • 15.8. Amgen Inc.
  • 15.9. C.H. Boehringer Sohn Ko. KG
  • 15.10. Novartis AG

16. Strategic Recommendations